Ensysce Biosciences financials
$0.4170+3.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $5.1M | $5.2M | $2.2M | $2.5M | $3.5M |
| Gross profit | $5.1M | $5.2M | $2.2M | $2.5M | $3.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$10.2M | -$6.7M | -$10.7M | -$24.2M | -$19.9M |
| Net income | -$10.2M | -$8.0M | -$10.6M | -$25.1M | -$29.9M |
| Net margin | −200.8% | −153.3% | −476.4% | −994.1% | −846.4% |
| Diluted EPS | $-3.98 | $-11.45 | $-70.40 | $-2091.30 | $-5335.20 |
| EBITDA | -$10.2M | -$6.7M | -$10.7M | -$24.2M | -$19.9M |
| Operating cash flow | -$7.8M | -$7.5M | -$10.8M | -$17.9M | -$8.2M |
| Free cash flow | -$7.9M | -$7.5M | -$10.8M | -$17.9M | — |
| Diluted shares | 2.6M | 0.7M | 0.2M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $4.3M | $3.5M | $1.1M | $3.1M | $12.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $306.7K | $301.7K | $854.7K | $4.4M | $20.8M |
| Total assets | $7.5M | $5.6M | $2.7M | $5.9M | $16.4M |
| Total liabilities | $4.6M | $2.2M | $3.4M | $9.9M | $24.6M |
| Shareholders' equity | $2.9M | $3.4M | -$651.3K | -$4.0M | -$8.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology